Vote on Clinical trials: - extracts from the vote - statement by Glenis WILLMOTT (S&D, UK), rapporteur EP Committee on Environment

Type: NEWS   Référence: 93867   Durée: 00:02:36   Première transmission: 29/05/2013  Lieu: Brussels, Belgium - EP
Fin de production: 29/05/2013
The Committee on Environment, Public Health and Food Safety voted on a legislative report on clinical trials, focussed on patient safety and transparency of trial results. The report urges for a change in the European laws on how clinical trials are authorised and carried out. The vote has been followed by a statement of the rapporteur Glenis WILLMOTT (S&D, UK). The rapporteur stressed out that the new rules would lead to the creation of many skilled jobs in Europe, as well as development of new life-saving treatments and drugs not just by pharmaceutical companies but also by medical research charities and academic institutions.

Only the original language version is authentic and it prevails in the event of its differing from the translated versions.
PDF version

00:00:00 Title 00:00:05
00:00:05 Exterior view of the European Parliament building in Brussels 00:00:05
00:00:10 General view of the ambience during the meeting (12 shots) 00:01:05
00:01:15 Announcement of the result of the vote on the electronic display board. Voting : 64, in favour : 62, against : 2, abstentions : 0 00:00:04
00:01:19 Applause after the result of the vote 00:00:05
00:01:24 SOUNDBITE (English) Glenis WILLMOTT (S&D, UK), rapporteur: "I am delighted with the result of the vote. We have a broad agreement across all political groups and I Know that all of the stakeholders would be pleased that we now go on Monday to negotiate straight away with the Council. That is really good. We have made a huge improvement to the existing the legislation. It is going to be much simpler. So we can do more trials in the EU because it has been a drop-off the number of trials conducted in Europe, about 25% because of the complicated nature of it. So it makes it easier to do trials, particularly cross-border, it would make it cheaper and simpler. We also got transparency in all the trials that we are doing which is a huge achievement. At the moment if you have a result of a trial it is not favourable, we do not know what the results are. People are going to have to publish the results whether the trials are successful or not and Member States can impose fines if the information is not made available when it should be." 00:00:58
00:02:22 Cutaways of the ambience during the meeting (2 shots) 00:00:14
00:02:36 End 00:00:00
Service Audiovisuel
Commission européenne
Conditions d'utilisation
© Commission européenne, 2016
© European Union, 2016